search
Back to results

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

Primary Purpose

Chronic Stable Heart Failure

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
spironolactone + furosemide
Sponsored by
Tottori University Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Stable Heart Failure focused on measuring heart failure, fibrosis, MMP, spironolactone, furosemide

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All Sexes

Inclusion Criteria:

  • chronic stable heart failure

Sites / Locations

    Outcomes

    Primary Outcome Measures

    MMP levels

    Secondary Outcome Measures

    Full Information

    First Posted
    April 18, 2008
    Last Updated
    April 18, 2008
    Sponsor
    Tottori University Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00663195
    Brief Title
    Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
    Official Title
    Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2008
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    December 2005 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Tottori University Hospital

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
    Detailed Description
    Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Stable Heart Failure
    Keywords
    heart failure, fibrosis, MMP, spironolactone, furosemide

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    16 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    spironolactone + furosemide
    Intervention Description
    spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
    Primary Outcome Measure Information:
    Title
    MMP levels
    Time Frame
    16 weeks

    10. Eligibility

    Sex
    All
    Eligibility Criteria
    Inclusion Criteria: chronic stable heart failure

    12. IPD Sharing Statement

    Learn more about this trial

    Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

    We'll reach out to this number within 24 hrs